1Aseptic processing and sterility assurance
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Inspection Record
Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy — FDA 483 Findings
Inspectors Liming ZhangThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
2Aseptic processing and sterility assurance
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
3Aseptic processing and sterility assurance
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
4Training and personnel
Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
5Stability and storage
Results of stability testing are not used in determining appropriate storage conditions and expiration dates.
About this record
Extracted automatically from the document US FDA published on 2020-03-18. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
